Press "Enter" to skip to content

FDA approves first treatment for post-partum depression

FDA approves Zulresso (brexanolone), the first drug for post-partum depression

Also Read:   Statement from FDA Commissioner Scott Gottlieb, M.D., and Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., on FDA’s ongoing scientific investigation of potential safety issue related to seizures reported following e-cigarette use, particularly in youth and young adults